Since the FDA approved its use for patients with renal diseases over three decades ago, EPO has also been reported to exert multifaceted neuroprotective and neurorestorative actions in addition to its hematopoietic effects in both preclinical and clinical stroke studies. Here, EPO is linked to kidney disorder.